Compare IRWD & RYAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRWD | RYAM |
|---|---|---|
| Founded | 1998 | 1926 |
| Country | United States | United States |
| Employees | N/A | 2325 |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.6M | 661.8M |
| IPO Year | 2009 | 2014 |
| Metric | IRWD | RYAM |
|---|---|---|
| Price | $4.48 | $7.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.67 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.7M | 1.0M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $298,276,000.00 | ★ $1,466,397,000.00 |
| Revenue This Year | $57.95 | N/A |
| Revenue Next Year | $4.39 | $8.22 |
| P/E Ratio | $19.46 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $0.67 | $3.35 |
| 52 Week High | $5.78 | $11.85 |
| Indicator | IRWD | RYAM |
|---|---|---|
| Relative Strength Index (RSI) | 62.31 | 37.11 |
| Support Level | $3.08 | $7.04 |
| Resistance Level | $4.50 | $7.75 |
| Average True Range (ATR) | 0.25 | 0.40 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 70.61 | 24.87 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.